NDATOPICALAEROSOL, FOAM
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
MEN'S ROGAINE (minoxidil) by Design Pharmaceuticals is clinical pharmacology 1. First approved in 2006.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Men's Rogaine is a topical foam formulation of minoxidil, a peripheral vasodilator originally developed for oral hypertension treatment. It is indicated for male pattern hair loss and works by enhancing microcirculatory blood flow to hair follicles, promoting hair growth and slowing hair loss. The topical route bypasses systemic vasodilatory effects seen with oral dosing, making it a localized treatment option.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, signaling potential team restructuring and strategic focus on brand loyalty and market defense.
Mechanism of Action
CLINICAL PHARMACOLOGY 1. General Pharmacologic Properties Minoxidil is an orally effective direct acting peripheral vasodilator that reduces elevated systolic and diastolic blood pressure by decreasing peripheral vascular resistance. Microcirculatory blood flow in animals is enhanced or maintained…
Worked on MEN'S ROGAINE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.